MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Life Sciences, Medical Devices & Health Information Technology
2025: Top 10 U.S. Biopharma Clusters 2025
New Jersey
*Industry: New Jersey
UroGen Pharma Inc. (NASDAQ: URGN)
Organization & Developments: UroGen
Parents
UroGen Pharma Inc. (NASDAQ: URGN)
Children
2018: UroGen Pharma: Interesting Interim Data, Look Out For Top Line Data - UroGen Pharma (NASDAQ:URGN)
2019: UroGen: Update After Data Release - UroGen Pharma Ltd. (NASDAQ:URGN)
2020: UroGen Pharma Announces Update on the Phase 2 Trial of an RTGel™ Hydrogel Formulation in Combination with BOTOX® (onabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary Incontinence
2021: Jelmyto And UGN-102 Will Likely Drive Strong Returns For UroGen Shareholders
2022: UroGen Pharma: Jelmyto Sales Growing Steadily, Concerns Remain_seekingalpha.com
2023: UroGen Pharma's Financial And Clinical Symbiosis (NASDAQ:URGN)
2023: Urogen: Binary Bet On UGN-102_seekingalpha.com
2024: UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
2024: UroGen Pharma: Choice Based On Near-Term High-Value PDUFA
2024: UroGen: All Eyes On UGN-102
2024: UroGen's JELMYTO Sales Surge 20% to $25.2M as FDA Fast-Tracks UGN-102 Review
2025: New Drug Eliminates Repeat Surgeries for 78% of Bladder Cancer Patients
2025: UroGen bladder cancer drug mitomycin wins FDA approval
2025: UroGen closes up 43% ahead of FDA decision on bladder cancer candidate
2025: UroGen crashes as FDA AdCom rebukes bladder cancer drug
2025: UroGen outlines $5B market opportunity as UGN-102 FDA review nears and commercial launch preparations accelerate
2025: UroGen Pharma: Lessons Learned And Future Outlook
2025: UroGen Pharma: ODAC Decision Puts Drug Approval In Limbo, But It's Not Over, Either
2025: UroGen: Despite ODAC Vote, Hope Remains With Targeting Of Other Cancer Subpopulation
2025: UroGen: Upcoming PDUFA, Some Concerns Remain
2025: UroGen's bladder cancer treatment to be reviewed by FDA advisory committee
Jumps
*Key People: UroGen
Finance & Acquisitions: UroGen